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Abstract
Introduction: Visfatin is a protein secreted by adipose tissue, which shows insulin mimetic properties. The role of visfatin in the develop-
ment of obesity, diabetes mellitus, and metabolic syndrome continues to raise controversy. The aim of the study was to evaluate visfatin
levels and to attempt to establish the relationship between visfatin and selected anthropometric and biochemical parameters in obese
individuals.
Material and methods: The study included 68 obese subjects (15 men and 53 women) aged 37.8 ± 13.2 years with body mass index (BMI)
values of 39.4 ± 6.4 kg/m2 without a previous diagnosis of abnormal glucose metabolism. The control group comprised 30 healthy non-
obese volunteers (6 men and 24 women) with normal glucose metabolism, aged 38.2 ± 14.9 years with BMI values of 22.8 ± 3.0 kg/m2.
Results: We found significantly higher visfatin levels in the obese subjects compared to the control group (median visfatin level of 39.6 v.
17.3 ng/ml, p = 0.0006). In the obese group there was a statistically significant negative correlation between visfatin levels and age (r = –0.26,
p = 0.034), waist-to-hip ratio (WHR) (r = –0.28, p = 0.031) and glycated haemoglobin (HbA1c) (r = –0.36, p = 0.0037). No statistically signifi-
cant correlations were found between visfatin levels and the remaining parameters under study. In the control group, visfatin levels did
not show any significant correlation with any of the parameters under study.
Conclusions: We found elevated levels of visfatin in obese subjects, which did not correlate with the majority of anthropometric param-
eters with the exception of WHR (negative correlation). This correlation may suggest that elevated visfatin levels are associated with the
distribution of adipose tissue characteristic of gynoid rather than visceral obesity. In the group of obese subjects, visfatin levels decreased
with age and glycated haemoglobin levels. (Pol J Endocrinol 2010; 61 (2): 169–173)
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Streszczenie
Wstęp: Wisfatyna jest białkiem wydzielanym przez tkankę tłuszczową , które wykazuje działanie insulinomimetyczne. Rola wisfatyny
w rozwoju otyłości, cukrzycy i zespołu metabolicznego jest nadal kontrowersyjna. Celem pracy była ocena stężenia wisfatyny i próba
znalezienia związku między wisfatyną a wybranymi parametrami antropometrycznymi i biochemicznymi u osób otyłych.
Materiał i metody: W badaniu wzięło udział 68 osób z otyłością (53 kobiety i 15 mężczyzn) w wieku 37,8 ± 13,2 lat, o wskaźniku masy ciała
(BMI, body mass index) 39,4 ± 6,4 kg/m2 bez rozpoznawanych dotychczas zaburzeń gospodarki węglowodanowej. Grupę kontrolną stano-
wiło 30 zdrowych ochotników (24 kobiety i 6 mężczyzn), bez otyłości i zaburzeń gospodarki węglowodanowej, w wieku 38,2 ± 14,9 lat,
o BMI 22,8 ± 3,0 kg/m2.
Wyniki: U osób otyłych stwierdzono istotnie wyższe stężenie wisfatyny w porównaniu z osobami z grupy kontrolnej (średnie stężenie
wisfatyny wyrażone jako mediana odpowiednio 39,6 v. 17,3 ng/ml; p = 0,0006). W grupie osób otyłych stwierdzono istotną statystycznie
ujemną korelację między stężeniem wisfatyny a wiekiem (r = –0,26; p = 0,034), stosunkiem obwodu talii do obwodu bioder (WHR, waist-
to-hip ratio) (r = –0,28; p = 0,031) i odsetkiem hemoglobiny glikowanej (HbA1c) (r = –0,36; p = 0,0037). Nie stwierdzono istotnych staty-
stycznie korelacji z pozostałymi ocenianymi parametrami. W grupie kontrolnej stężenie wisfatyny nie korelowało istotnie z żadnym
z ocenianych parametrów.
Wnioski: U osób otyłych stwierdzono podwyższone stężenie wisfatyny, które nie korelowało z większością parametrów antropometrycz-
nych, poza WHR (korelacja ujemna). Stwierdzona korelacja może sugerować, że podwyższone stężenia wisfatyny wiążą się raczej
z rozkładem tkanki tłuszczowej typowym dla otyłości typu gynoidalnego, a nie dla otyłości trzewnej. W badanej przez autorów pracy
grupie osób otyłych stężenie wisfatyny malało z wiekiem i wraz ze wzrostem stężenia hemoglobiny glikowanej.
(Endokrynol Pol 2010; 61 (2): 169–173)
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Introduction
Visfatin is a 52-kDa protein originally identified as pre-B
cell colony-enhancing factor (PBEF) and showing nico-
tinamide phosphoribosyl transferase activity [1, 2]. The
protein is synthesised by bone marrow cells, activated
lymphocytes, liver cells, and skeletal muscle cells [1].
Fukuhara et al. discovered, however, that the largest
source of visfatin is visceral adipose tissue [3]. In addi-
tion to being secreted by adipocytes, visfatin is also se-
creted by macrophages infiltrating adipose tissue [4].
Plasma levels of this adipocytokine have been shown
to positively correlate with the amount of visceral adi-
pose tissue determined by computed tomography [3].
Visfatin shows an affinity for the insulin receptor.
The protein activates the insulin receptor by binding to
it at a different site from insulin. The insulin-mimetic
actions of visfatin involve decreasing glucose uptake by
insulin-sensitive cells (adipocytes and myocytes) and
inhibiting glucose release by liver cells. In addition, vis-
fatin promotes the storage of triglycerides in preadipo-
cytes and stimulates adipogenesis [3]. The discovery of
visfatin, which could be the link between visceral obe-
sity and abnormal glucose metabolism, has generated
considerable interest in this protein.
The results of visfatin studies conducted so far in
obese individuals are, however, controversial and fail
to unequivocally explain the relationship between this
adipocytokine and obesity or glucose metabolism ab-
normalities.
The aim of this study was to evaluate visfatin levels
in obese individuals and to attempt to establish the re-
lationship between visfatin and selected anthropo-
metric and biochemical parameters.
Material and methods
The study included 68 obese subjects (15 men and
53 women) without a previous diagnosis of abnormal
glucose metabolism in whom, based on their medical
history, physical examination, and the assessment of
hormone levels (thyroid-stimulating hormone (TSH),
cortisol, prolactin), the most common secondary caus-
es of obesity had been ruled out.
The control group comprised 30 healthy individu-
als (6 men and 24 women) with body mass index (BMI)
values within normal limits and with normal glucose
values at baseline and at 2 hours in the oral glucose tol-
erance test (OGTT) using 75 g of glucose.
In each of the subjects in both groups, we measured
body mass, height, waist circumference, and hip circum-
ference, calculated BMI and waist-to-hip ratio (WHR),
and performed an OGTT. Table I summarises the char-
acteristics of both groups: the study group and the con-
trol group.
In the study group we additionally measured total
cholesterol, LDL-cholesterol, HDL-cholesterol, triglyc-
erides, uric acid, C-peptide, glycated haemoglobin
(HbA1c), and creatinine. Table II summarises the mean
values of these parameters. Visfatin was measured in
both groups by enzyme immunoassay (Visfatin C-ter-
minal (Human), Phoenix Pharmaceuticals).
All the subjects, having read the patient informa-
tion, provided informed consent to participate in the
study. The study was approved by the Bioethics Com-
mittee of the Medical College at Nicolaus Copernicus
University in Toruń, Poland.
We performed statistical analysis of the results, cal-
culating arithmetic means, standard deviations, medi-
Table I. Characteristics of the study groups
Tabela I. Charakterystyka badanych grup
Parameter (unit) Study group Control group p value
Mean ± SD Min Max Mean ± SD Min Max
Age (years) 37.8 ± 13.2 17 69 38.2 ± 14.9 20 67 0.8817
Body mass [kg] 110 ± 19.9 75 182.7 67.2 ± 12.6 49 95 0.0000
Height [cm] 167.1 ± 8.6 151 192 171 ± 9.8 155 192 0.0497
BMI [kg/m2] 39.4 ± 6.4 30.7 63.2 22.8 ± 3.0 17.9 24.3 0.0000
Waist circumference [cm] 115.2 ± 14.3 91 170 80.3 ± 12.9 62 110 0.0000
Hip circumference [cm] 126 ± 12.9 103 166 97.7 ± 9.8 77 116 0.0000
WHR 0.918 ± 0.106 0.710 1.21 0.819 ± 22.1 0.65 0.97 0.000027
BMI — body mass index; max — maximum value; min — minimum value; SD — standard deviation; WHR — waist-to-hip ratio
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ans, minima, and maxima. We used the Shapiro-Wilk
test to assess the normality of the distribution of the
study variables. In the case of samples characterised by
a near-normal distribution, the means were compared
with the use of Student’s t-test for independent vari-
ables. Where a distribution significantly differed from
the normal distribution, the significance of between-
group comparisons was verified using the non-para-
metric Mann-Whitney U test. The relationship between
two variables was assessed with Pearson’s linear corre-
lation coefficient. A significance level of 0.05 was adopt-
ed. All the calculations were performed using the Sta-
tistica suite.
Results
We found significantly elevated visfatin levels in the
group of obese individuals versus the control group
(median visfatin level of 39.6 v. 17.3 ng/ml, p = 0.0006).
The mean values of the remaining parameters assessed
in the control group are given in Table II.
We found a statistically significant negative correla-
tion between visfatin levels and age, HbA1c and WHR
in the group of obese individuals with no statistically
significant correlations between visfatin levels and the
other parameters assessed. In the control group there
were no correlations between visfatin levels and any of
the parameters assessed (Table III).
Based on the OGTT, we diagnosed diabetes melli-
tus, impaired fasting glucose, or impaired glucose tol-
erance in 31 subjects with no glucose metabolism ab-
normalities in the remaining 37 subjects. Visfatin levels
in both subgroups of obese subjects, those with and
those without abnormal glucose metabolism, did not
differ with median visfatin levels of 40.86 and 57.70 ng/
ml, respectively (p = 0.1939).
Table III. Correlations between visfatin and the parameters evaluated in the study group and the control group
Tabela III. Korelacje między stężeniem wisfatyny a ocenianymi parametrami w grupie badanej i kontrolnej
Parameter (unit) Study group Control group
r p value r p value
Age (years) –0.26 0.034 –0.35 0.051
Body mass [kg] 0.07 0.594 –0.20 0.250
Height [cm] 0.15 0.217 –0.05 0.780
BMI [kg/m2] –0.03 0.822 –0.26 0.161
Waist circumference [cm] 0.06 0.632 –0.22 0.246
Hip circumference [cm] 0.24 0.061 –0.12 0.525
WHR –0.28 0.031 –0.22 0.247
Fasting glucose [mg/dl] –0.23 0.060 –0.1194 0.530
Total cholesterol [mg/dl] 0.01 0.944 – –
LDL-cholesterol [mg/dl] –0.03 0.831 – –
HDL-cholesterol [mg/dl] –0.02 0.867 – –
Triglycerides [mg/dl] 0.05 0.687 – –
C-peptide [ng/dl] 0.01 0.962 – –
HbA1c (%) –0.36 0.0037 – –
Uric acid [mg/dl] –0.03 0.802 – –
Creatinine [mg/dl] –0.13 0.337 – –
Table II. The mean values of the parameters evaluated in the
study group
Tabela II. Średnie wartości ocenianych parametrów w ba-
danej grupie
Parameter (unit) Mean ± SD Minimum Maximum
Total cholesterol 189.3 ± 29.4 136 280
[mg/dl]
LDL-cholesterol 114 ± 26.4 59 206
[mg/dl]
HDL-cholesterol 47.2 ± 8.3 30 69
[mg/dl]
Triglycerides 140.3 ± 67.2 41 323
[mg/dl]
C-peptide [ng/dl] 3.01 ± 1.99 1.01 12.8
HbA1c (%) 5.79 ± 0.80 4.6 8.6
Uric acid [mg/dl] 5.2 ± 1.61 2.5 10.0
Creatinine [mg/dl] 0.8 ± 1.12 0.55 1.08
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Discussion
The pioneering studies by Fukuhara showed that plas-
ma visfatin levels strongly correlated with the quantity
of visceral adipose tissue (r = 0.68, p < 0.001) assessed
by computed tomography with a weaker correlation
with the quantity of subcutaneous adipose tissue
(r = 0.22, p < 0.05) [3]. Plasma visfatin levels and the
expression of visfatin mRNA in visceral and subcuta-
neous adipose tissue in lean individuals and in individ-
uals with various degrees of obesity were investigated
by Berndt et al., who demonstrated a positive correla-
tion between visfatin levels and the expression of visfa-
tin mRNA in the visceral adipose tissue, BMI and the
percentage body fat. In contrast to Fukuhara, Berndt et
al. did not demonstrate any relationship between vis-
fatin levels and the amount of visceral adipose tissue
the mass of which was also assessed by computed to-
mography. However, plasma visfatin levels did not cor-
relate with the expression of visfatin mRNA in the sub-
cutaneous adipose tissue [5]. Pagano et al., on the other
hand, showed that visfatin levels and visfatin mRNA
expression were lower in subcutaneous and higher in
visceral adipose tissue of obese subjects versus lean in-
dividuals. In the obese individuals, plasma visfatin lev-
els and the expression of visfatin mRNA showed a neg-
ative correlation with BMI, with the expression of
mRNA in the visceral adipose tissue showing a positive
correlation with BMI. Based on the positive correlation
between visfatin levels and the expression of visfatin
mRNA in the subcutaneous adipose tissue, the authors
concluded that it is the subcutaneous tissue that deter-
mines plasma visfatin levels. They also drew attention
to the fact that the subcutaneous adipose tissue is re-
sponsible for only 30% of circulating visfatin. Reduced
secretion of visfatin by the remaining sources, such as
the skeletal muscles, the liver, and immune cells in obese
individuals, may be the cause of the reduced plasma
levels of this adipocytokine [6].
We found significantly higher visfatin levels in the
obese subjects compared to the lean subjects, which did
not, however, correlate with BMI or waist circumfer-
ence. We did notice a significant negative correlation
between visfatin levels and age, HbA1c and WHR.
Haider et al. also confirmed significantly higher plasma
visfatin levels in patients with morbid obesity compared
to lean individuals [7]. Zahorska-Markiewicz et al.
also reported higher visfatin levels in obese versus lean
women [8]. Garcia-Fuentes et al. found that patients
with morbid obesity are characterised by significantly
higher visfatin levels compared to lean individuals but
only when obesity is associated with glucose metabo-
lism abnormalities [9]. On the other hand, in the above-
referenced paper by Pagano et al. [6] and in a study by
Jian et al. [10], obese subjects had significantly lower
visfatin levels compared to subjects with normal body
weight. Other researchers have not reported differenc-
es in visfatin levels between obese and lean subjects [11].
Similarly, very disparate results have been obtained
regarding correlations between visfatin levels and an-
thropometric parameters in the obese. Some studies [5]
have demonstrated positive, while others [6, 10] nega-
tive correlation between visfatin levels and BMI. The
lack of correlation between visfatin levels and BMI or
waist circumference in our study is consistent with find-
ings obtained by other authors [12–14]. Visfatin levels
in the obese subjects participating in our study showed
a negative correlation with WHR. We also observed
a positive correlation, almost statistically significant, be-
tween visfatin levels and hip circumference, which
means that the more the body silhouette corresponds
to the gynoid type of obesity with a predominance of
hip circumference over waist circumference, the high-
er the visfatin levels. Our results show that elevated
visfatin levels are associated with the adipose tissue dis-
tribution pattern typical of gynoid rather than visceral
obesity. This might suggest that visfatin levels are de-
termined by the subcutaneous adipose tissue located
in the thighs and buttocks rather than by the visceral
adipose tissue. It should, however, be taken into con-
sideration that most of the subjects in our study were
women (72%), in whom the most prevalent type of obe-
sity is the gynoid type, which is associated with fat ac-
cumulation in the buttocks and thighs. The study by
Jian et al., which analysed a subgroup of obese men,
found a positive correlation between visfatin levels and
WHR, which, according to the authors, might suggest
the involvement of visfatin in the pathogenesis of vis-
ceral obesity in men [10].
In the group of obese subjects we found a signifi-
cant negative correlation between visfatin levels and
age. This correlation was also reported by Luis et al.,
who demonstrated that visfatin levels decreased by an
average of 4.1 ng/ml with each year of life [14].
In our study, visfatin levels did not differ significant-
ly whether or not obesity was accompanied by abnor-
mal glucose metabolism, which is consistent with the
findings obtained by other authors who evaluated vis-
fatin levels in obese individuals recently diagnosed with
glucose metabolism abnormalities [10, 11]. On the oth-
er hand, in patients with longer-standing type 2 diabe-
tes mellitus, visfatin levels are higher than in non-dia-
betics [12, 15]. In a study by Lopez-Bermejo, visfatin lev-
els increased with progressive pancreatic beta-cell dys-
function and with increasing HbA1c, which reflects
long-term glucose control [12]. According to the authors,
the increase in the level of visfatin, which shows an in-
sulin-mimetic effects, is a compensatory mechanism that
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develops in endogenous insulin deficit in patients with
longer-standing type 2 diabetes mellitus.
We enrolled obese patients without a previous di-
agnosis of abnormal glucose metabolism. In some of
them, based on an OGTT, we diagnosed prediabetes or
type 2 diabetes mellitus. In the entire group of obese
subjects we found a negative correlation between vis-
fatin levels and HbA1c. This means that lower visfatin
levels accompanied higher glucose values in the peri-
od of three months preceding the measurement of
HbA1c. This is a correlation that is opposite to that found
in the above-referenced study conducted in patients
previously diagnosed with type 2 diabetes mellitus, with
endogenous insulin deficiency (more than a third of the
patients were being managed with insulin) [12]. Obese
patients with preserved insulin secretion participated
in our study (the mean C-peptide level in the entire
group was 3.01 ± 1.99 ng/dl), and this is the most likely
explanation for the negative correlation between visfa-
tin levels and HbA1c that we observed, which was in
opposition to the findings of Lopez-Bemejro et al. [12].
This correlation was also demonstrated by Li et al. in
a group of individuals who had recently been diagnosed
with glucose metabolism abnormalities [16]. The poten-
tial mechanism explaining the negative correlation be-
tween visfatin and glycated haemoglobin observed by
us remains unclear. In the study by Haider, conducted
in healthy volunteers, visfatin levels increased follow-
ing an intravenous infusion of glucose, while an intra-
venous infusion of insulin that was being administered
in parallel to the glucose infusion suppressed the secre-
tion of visfatin [17]. It may, therefore, be hypothesised
that in endogenous insulin deficit, hyperglycaemia rais-
es visfatin levels, and where the function of pancreatic
beta cells is preserved, visfatin secretion may be sup-
pressed by insulin.
Conclusions
We found elevated levels of visfatin in obese subjects
which did not correlate with the majority of anthropo-
metric parameters we evaluated, with the exception of
WHR (negative correlation). This correlation may sug-
gest that elevated visfatin levels are associated with the
distribution of adipose tissue characteristic of gynoid
rather than visceral obesity. In the group of obese sub-
jects, visfatin levels decreased with age and glycated
haemoglobin levels.
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